Pediatric adverse event review
Executive Summary
The Pediatric Advisory Committee will meet April 11 to review adverse event reports for Novartis' Lescol (fluvastatin) and Sandostatin (octreotide) and generics. The panel will also hear updates to adverse event reports requested by PAC for Roche's Xenical (orlistat) and Johnson & Johnson's Ditropan (oxybutynin)...